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A B S T R A C T
Background: Bipolar disorder (BD) and schizophrenia (SZ) are characterized by neurocognitive and
functional deficits with marked heterogeneity. It has been suggested that BD with a history of psychotic
symptoms (BD-P) could constitute a phenotypically homogeneous subtype characterized by greater
neurocognitive and functional impairments, or by a distinct trajectory of such deficits. The aim of this
study was to compare the neurocognitive and functional course of euthymic BD-P, euthymic BD patients
without a history of psychosis (BD-NP), stabilized patients with schizophrenia and healthy subjects,
during a five-year follow-up.
Methods: Neurocognitive and psychosocial function was examined in 100 euthymic patients with BD (50
BD-P, 50 BD-NP), 50 stabilized patients with schizophrenia (SZ), and 51 healthy controls (HC) at baseline
(T1), and after a 5-year follow-up (T2).
Results: The course of both neurocognitive performance and functional outcome of patients with SZ and
BD (BD-P and BD-NP) is stable. The profile of neurocognitive impairment of patients with SZ or BD (BD-P
and BD-NP), is similar, with only quantitative differences circumscribed to certain domains, such as
working memory. The subgroup of patients with BD-NP does not show functional deterioration.
Conclusions: We have not found evidence of progression in the neurocognitive or psychosocial
impairment in any of the three groups of patients, although it cannot be dismissed the possibility of a
subset of patients with a progressive course. Other longitudinal studies with larger samples and longer
duration are necessary to confirm these findings.
© 2018 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
European Psychiatry
journal homepage: htt p: / /www.europsy- journa l . com1. Introduction
Bipolar disorder (BD) is characterized by neurocognitive [1,2]
and functional [3,4] deficits which are a core feature of the
disorder. However, a marked clinical [5,6], neurocognitive [7,8] or
functional [9,10] heterogeneity has been reported, in a way that, at
one end, some patients with BD seem to reach a level of* Corresponding author at: Department of Psychiatry, Hospital Virgen de La Luz,
C/Hermandad Donantes de Sangre 1, 16002, Cuenca, Spain.
E-mail address: jlsantosg@sescam.jccm.es (J.L. Santos).
http://dx.doi.org/10.1016/j.eurpsy.2018.11.008
0924-9338/© 2018 Elsevier Masson SAS. All rights reserved.psychosocial [10] and neurocognitive [11,12] functioning similar
to that of healthy subjects, in contrast, at the other end, with
individuals who show a severe neurocognitive and functional
impairment [13,14].
As with BD, schizophrenia is a heterogeneous disorder which
is also associated with high levels of neurocognitive and
psychosocial impairment [15,16]. Moreover, it has been shown
that BD and SZ share a substantial genetic risk, although there are
also specific loci which are responsible for the phenotypic
differences existing between both disorders [17]. Thus, the
comparison of the neurocognitive and psychosocial functioning
of patients with BD and SZ has not only clinical interest, but it is
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physiological mechanisms.
It has been suggested that patients with BD with a history of
psychotic symptoms (BD-P) could constitute a phenotypically
homogeneous subtype characterized by a greater neurocognitive
[18,19] and functional [20,21] impairment. Thus, some authors
have suggested that BD-P could occupy an intermediate position
between patients with schizophrenia (SZ) and patients with BD
without a history of psychotic symptoms (BD-NP) [22,23].
However, a number of cross sectional studies [24–26], including
those from our group [27–29], did not find any relevant difference
of neurocognitive and functional performance between BD-P and
BD-NP, showing only subtle differences, and circumscribed to
certain neurocognitive domains, such as working memory [28], or
to specific areas of functioning, such as financial issues or
occupational functioning [29,30].
To the date, most longitudinal studies have shown stability in
the neurocognitive deficit of patients with BD [2,31–33]. Similarly,
no progression of the functional deficit has been found [34,35].
Nevertheless, it cannot be dismissed the possibility of the
existence of a subset of patients with BD showing a progression
of neurocognitive or functional outcome [36,37]. In this regard,
both cross-sectional and longitudinal studies have pointed out that
the neurocognitive and functional trajectory may be mediated by
the clinical course [38,39]. Thus, some studies have suggested the
possibility that clinical characteristics, such as the presence of
episodes with psychotic symptoms, have a deleterious effect on the
neurocognitive or functional trajectory of this disorder, although
there are discrepant results [20,28,29,40–43]. Long-term studies
are necessary to confirm these results [44].
To further extend our previous studies, we have carried out a 5-
year follow-up study aimed at comparing: 1) the course of
neurocognitive dysfunction in a group of bipolar patients with and
without a history of psychotic symptoms and a group of patients
with schizophrenia, in relation to a healthy control group, 2) the
course of functional impairment in these three groups of patients
in relation to the control group, and 3) the severity of neuro-
cognitive and functional impairment of the three groups of
patients. We hypothesized that neurocognitive and functional
deficits have a stable course both in patients with bipolar disorder
and in patients with schizophrenia. Likewise, considering our
previous results, we also hypothesized that there are no significant
neurocognitive or functional differences between the two groups
of patients with bipolar disorder.
2. Material and methods
2.1. Sample
Participants were enrolled in the Cuenca Bipolar Disorder
Follow-up Study, a prospective study carried out at the Department
of Psychiatry of the Hospital Virgen de la Luz de Cuenca (Castilla-La
Mancha, Spain). The study was approved by the Clinical Research
Ethics Committee of the Cuenca Health Area. All subjects gave
written informed consent, after a complete description of the
procedures and prior to enrolment in the study.
The description of the sample was extensively collected in
previous cross-sectional studies [28,29]. Briefly, 100 patients with
bipolar disorder type I, 50 of them who had a lifetime history of
psychosis and 50 who had never presented psychotic symptoms,
and 50 patients with schizophrenia were included in the study. All
patients met DSM-IV criteria for schizophrenia or bipolar disorder.
The diagnoses were confirmed by the Structured Clinical Interview
for DSM-IV (SCID-I). The presence or absence of a history of
psychotic symptoms (delusions and/or hallucinations) was estab-
lished using the SCID–I, after carrying out a comprehensive reviewof the psychiatric chart. Variables of the course of illness such as
the number of episodes and number of hospitalizations recorded
both at baseline, and during the five-year follow up, were also
ascertained reviewing the medical chart.
Patients with BD were euthymic for at least three months prior
to the assessments. Euthymia was defined according to the
following criteria [45]: a score fewer than 7 points on the
Hamilton Depression Rating Scale (HAM-D) and a score fewer than
6 points on the Young Mania Rating Scale (YMRS). In addition,
these scores remained below that threshold in three consecutive
monthly evaluations. Moreover, all patients with SZ were clinically
stabilized, at least during the three months before the assessments,
according to criteria used in previous studies [27–29].
The exclusion criteria were as follows: (i) comorbid medical
disease which can cause neurocognitive impairment, (ii) neuro-
psychiatric illness, other than SZ or BD, associated with cognitive
impairment, (iii) drug abuse or dependence in the last 24 months,
except nicotine and caffeine, (iv) a history of electroconvulsive
therapy, (v) a history of brain trauma with loss of consciousness,
(vi) less than six years of education, (vii) current IQ score lower
than 70, (viii) refusal to sign written informed consent.
Fifty-one healthy controls (HC), matched with patients for age,
gender and years of education, were enrolled in the study. In order
to rule out the presence of psychiatric disorders, all control
subjects were assessed with the SCID-I. The control group met the
same exclusion criteria as patients, adding as an additional
criterion for exclusion in this group the presence of some first-
degree relative diagnosed with a severe mental disorder (bipolar
disorder or psychosis). The control subjects were living in the same
catchment area and had the same ethnic origin as patients.
Both patients and HC were clinical, neuropsychologically and
functionally assessed at two time points: at the beginning of the study
(T1), and after a five-year follow-up (T2). The same inclusion and
exclusion criteria considered at T1 were used at T2, thus euthymia and
stability, as previously defined, were present in all subjects.
2.2. Clinical and functional assessment
Clinical assessments were carried out using the Spanish version
of the following scales: The Positive and Negative Symptoms Scale
(PANSS) [46], the Hamilton Depression Rating Scale [47], and the
Young Mania Rating Scale [48].
Functional performance was evaluated using the Functioning
Assessment Short Test (FAST) [49], and the function dimension of
the split version of the Global Assessment of Functioning scale
(GAF-F) [50]. The GAF-F is a 100-point scale reflecting functioning
which scores from 1, representing the most severe impairment, to
100, representing the least impaired individual. The FAST is a scale
which was primarily developed to assess psychosocial functioning
in bipolar disorder [49], but that was later validated for
schizophrenia [51,52]. This 24-items scale evaluates impairment
during the last two weeks in six specific areas of functioning:
autonomy, occupational functioning, cognitive functioning, finan-
cial issues, interpersonal relationships and leisure time. Each item
is scored on a 0–3-point scale (0: no difficulty, 1: mild difficulty, 2:
moderate difficulty, 3: severe difficulty; total score ranges from 0 to
72 points), thus higher scores indicate poorer performance.
For every patient, the information was obtained from the
participant, and at least, from a second source of reliable
information (family, caregiver or case-management).
2.3. Neuropsychological assessment
Six neurocognitive domains, which correspond mostly to the
domains included in the MATRICS Consensus Cognitive Battery
[53], were evaluated through 12 neurocognitive measures, as
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WAIS-III digit-symbol coding subtest, Category Fluency Test
(animal naming); 2) Working Memory. WAIS-III digit span
backward subtest, letter-number sequencing subtest of the
Wechsler Memory Scale (WMS-III); 3) Attention/vigilance. De-
graded Stimulus Continuous Performance Test (DS-CPT); 4) Verbal
Learning and Memory. California Verbal Learning Test (CVLT); 5)
Visual memory. Rey–Osterrieth Complex Figure Test (ROCFT); 6)
Executive Functions. Wisconsin Card Sorting Test (WCST), Stroop
Test interference, Trail Making Test–Part B (TMT-B), FAS test. The
value of the Cronbachs alpha for the six neurocognitive domains
was 0.721 for speed of processing, 0.586 for working memory,
0.828 for executive function, 0.937 for visual memory, 0.826 for
verbal memory, and 0.854 for attention. Additionally, premorbid IQ
was determined using the vocabulary subtest of the Wechsler
Adult Intelligence Scale WAIS-III.
2.4. Statistical analysis
The IBM SPSS Statistics 24 (Chicago IL, USA) for Windows was
used for data analysis. Firstly, we examined if the study variables
were normally distributed, and transformations were performed
when necessary. For demographic and symptomatic variables,
group differences were evaluated using one-way analysis of
variance (ANOVA) (continuous variables) or chi-square test
(categorical variables). For the analysis of neurocognitive perfor-
mance, each measure in both T1 and T2 was first converted into z-
scores based on controlsscores at T1. Data were also transformedTable 1
Sociodemographic and clinical variables in patients with bipolar disorder with and witho





Females No (%) 17 (47.2) 20 (58.8)
Age (years) 42.6 (13.2) 42.1 (12.
Education (years) 12.7 (3.0) 12.7 (4.0
Age at onset (years) – 28.3 (9.1
Duration of illness (years) – 13.9 (10.1
HAM-D score at T1 1.3 (1.1) 2.8 (2.1) 
YMRS score at T1 0.3 (0.7) 0.3 (1.1) 
HAM-D score at T2 1.6 (1.4) 2.8 (2.4) 
YMRS score at T2 0.7 (0.9) 1.5 (2.3) 
PANSS-T score at T1 
PANSS-P score at T1 
PANSS-N score at T1 
PANSS-PG score at T1 
PANSS-T score at T2 
PANSS-P score at T2 
PANSS-N score at T2 
PANSS-PG score at T2 
Premorbid IQ 100.0 (10.0) 98.3 (15.
No. hospitalizations at T1 – 2.5 (4.8) 
No. hospitalizations for depression at T1 – 1.29 (4.8
No. hospitalizations for mania at T1 – 1.15 (1.5)
No. of depressive episodes at T1 – 10.59 (10
No. of manic/hypomanic episodes at T1 – 3.65 (4.8
No. total of episodes at T1 – 19.00 (17
Course of illness during the follow up period.
No. of hospitalizations – 0.61 (1.1)
No. of hospitalizations for depression – 0.24 (0.7
No. of hospitalizations for mania – 0.33 (0.6
No. of hospitalizations for psychosis (non-affective) – – 
No. of depressive episodes 1.88 (3.3
No. of manic/hypomanic episodes 1.64 (2.8
No. total of episodes 3.48 (5.9
HC: Healthy controls; BD-NP: Patients with bipolar disorder without history of psychotic s
SZ: Patients with schizophrenia; T1: at baseline; T2: at follow-up of five years; HAM-D: Ha
and Negative Syndrome Scale total score; PANSS-P = Positive and Negative Syndrome Sc
symptoms; PANSS-PG = Positive and Negative Syndrome Scale-General psychopatholog
aOnly BD-P and BD-NP were analyzed.so that higher scores always indicated better performance. The z-
scores that were obtained approached a normal distribution with a
mean of 0 and a standard deviation of 1. Scores of neurocognitive
domains composed of more than one measure were obtained by
averaging the z-scores of all measures in the domain. Also, a
neurocognitive composite index (NCI) was calculated by averaging
the scores obtained in each cognitive domain.
To assess longitudinal neurocognitive and functional perfor-
mance, repeated measures ANOVAwas used for each neurocognitive
and functional measure including the normalized T1 and T2 values
based on controls T1 mean and standard deviation, in order to adjust
each change comparison for the baseline values. Effects of group,
time, and group-by-time interactions were examined. Bonferroni
test was used for post hoc analyses. Scores on affective symptom
scales (HAM-D and YMRS) were used as covariates when significant
differences between groups were found.
3. Results
One-hundred and fifty patients (50 BD-P, 50 BD-NP, 50 SZ), and 51
HC were initially included in this study. At the end of the 5-year
follow-up, 37 patients (6 BP-P,16 BD-NP,15 SZ) were lost. Of these, 2
patients died (committed suicide), 12 did not meet the inclusion
criteria at T2, and 23 patients refused to be evaluated at T2. Similarly,
15 HC refused to be assessed at T2. We found no significant
differences in demographic, clinical, cognitive, functional, or
treatment variables at T1 between subjects who completed and






 23 (52.3) 17 (48.6) 0.772
2) 40.6 (10.7) 39.1 (9.2) 0.571
) 12.3 (3.4) 12.1 (2.9) 0.858
) 24.6 (9.1) 23.1 (5.6) 0.028 SZ < BD-NP
) 16.3 (10.7) 16.0 (7.5) 0.532
2.6 (2.2) 3.7 (2.1) 0.000 BD-NP, BD-P, SZ > HC
0.4 (0.1) 1.2 (2.05) 0.009 SZ > BD-P, BD-NP, HC
3.0 (2.8) 3.9 (2.5) 0.002 SZ>HC









0) 92.8 (12.8) 91.2 (12.5) 0.008 HC > BD-P, SZ
4.11 (4.8) 3.31 (3.6) 0.272
) 1.14 (2.5) – 0.852 a
 2.98 (4.0) – 0.007 a BD-P > BD-NP
.6) 7.73 (7.2) – 0.182 a
) 5.95 (5.3) – 0.050 a
.7) 15.84 (15.4) – 0.405 a
 0.89 (1.4) 1.09 (1.8) 0.409
5) 0.32 (1.1) 0.09 (0.38) 0.726a
) 0.52 (1.0) – 0.337a
– 0.97 (1.7)
) 1.82 (2.7) 0.21 (0.6) 0.929a
) 1.57 (2.1) – 0.905a
) 3.34 (4.3) 0.902a
ymptoms; BD-P: Patients with bipolar disorder with history of psychotic symptoms;
milton Depression Rating Scale; YMRS: Young Mania Rating Scale; PANSS-T: Positive
ale-Positive symptoms; PANSS-N = Positive and Negative Syndrome Scale-Negative
y; IQ: Intelligence quotient.
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63.8 months [standard deviation (SD) = 5.2 months; range: 55–78
months] for patients and 62.4 months (SD = 8.1 months; range: 51–
76 months) for the control group (p = 0.331; F = 0.953).
Table 1 shows sociodemographic and clinical characteristics of
patients and control subjects which completed the follow-up.
There were no significant differences between the four groups at
baseline either for age, years of education or for gender
distribution. HC had higher premorbid IQ than patients with
BD-P and SZ. The three groups of patients scored higher on the
HAM-D than HC at T1, although, at the end of the follow-up period,
differences were only found between HC and SZ. Moreover, on the
YMRS, patients with SZ scored higher than patients with BD and HC
at T1.
Comparing the three groups of patients, no differences were
found in years of evolution of illness. Nevertheless, patients with
SZ had an earlier onset than BD-NP. When we compared the course
of illness between BD-P and BD-NP, at baseline, patients did not
differ in number of hospitalizations, number of hospitalizations for
depression, or number of episodes (total, depressive or manic/
hypomanic), differing however on number of hospitalizations for
mania, which were significantly higher in BD-P than in BD-NP. The
characteristics of pharmacological treatment are displayed in
Table 2. A greater number of patients with BD-P (Chi2 = 11.857;
df:1; p < 0.001), but no of patients with BD-NP (Chi2 = 2.893; df:1;
p < 0.089) received antipsychotic treatment at T2 in relation to T1.
3.1. Neurocognitive function
Table 3 shows the z-scores and results of the repeated-measures
ANOVA for each neurocognitive measure (See Fig.1 and Supplemen-
tal Fig. 1). We found an effect of time on some cognitive measures
included in the domains executive function and attention (worse
performance both at T2 than at T1 in the domain of attention, and at
T1 than at T2 in executive function). However, we didnot find a group
x time interaction for any cognitive measure.
We found an effect of group for each neurocognitive measure,
except for recognition (verbal memory domain) and verbal fluency.Table 2











Lithium (monotherapy) 13 (38.2%) 13 (29.5%) – 
Anticonvulsant (monotherapy) 12 (35.3%) 9 (20.5%) – 
Lithium + Anticonvulsant 5 (14.7%) 11 (25%) – 
Lithium + SGA 3 (8.8%) 5 (11.4%) – 
Lithium + Anticonvulsant + SGA 0 (0%) 3 (6.8%) – 
Anticonvulsant + SGA 2 (5.9%) 2 (4.5%) – 
SGA without MS 0 (0%) 2 (4.5%) 35 (100
SGA (with or without MS) 5 (14.7%) 11 (25%) 35 (100
Antidepressants 9 (26.5%) 10 (22.7%) 6 (17.1%







Number of MS 1.09 (0.29) 1.23 (0.52) – 
Total number of psychotropic drugs 1.71 (0.87) 2.02 (0.88) 1.83(0.9
Lithium levels (mEq / L) 0.68 (0.11) 0.71 (0.19) – 
Dosage of antipsychotic (E-CPZ) 205.00 (125.5) 226.64 (150.0) 452.1 (2
T1: at baseline; T2: at follow-up of five years; BD-NP: Patients with bipolar disorder witho
of psychotic symptoms; SZ: Patients with schizophrenia; SGA: Second-generation antip
* Comparisons only between BD-P and BD-NP.
1 Chi2.
2 Mann-Whitney U test.
3 Kruskal Wallis Test.The results of the post-hoc tests (Bonferroni test) are shown in
Table 4. For the NCI, HC had higher scores than patients.
Nevertheless, no significant differences were found between the
three groups of patients. Similar results were found for the
domains speed processing, verbal memory, visual memory and
executive function. For the domains attention and working
memory, HC scored higher than BD-P and SZ, but not than BD-
NP. Additionally, in the working memory domain, there were
significant differences between BD-NP and SZ. We only found
differences between BD-P and BD-NP in one measure of the
domain working memory (letter and number).
3.2. Psychosocial functioning
Repeated-measures ANOVA showed group x time interaction
for no functional measure (Table 5), although there was an effect of
time on the GAF-F (worse performance at T2 than at T1).
We found an effect of group foreach functional measure (Table 5).
The results of the post-hoc tests are shown in Table 4. There were
differences between HC and BD-NP in no functional measure, except
for the subscale of the FAST leisure time. However, HC had better
performance than BD-P in the two measures of overall functioning
and in the subscales occupational functioning, interpersonal
relationships and leisure time. Additionally, HC had better perfor-
mance than SZ in all functional measures.
BD-NP had better performance than BD-P in the two measures
of overall functioning and the subscales occupational functioning
and interpersonal relationships. Furthermore, BD-NP had better
performance than SZ in all functional measures, except for
financial issues. BD-P had better performance than SZ in the
measures of overall functioning (GAF-F and FAST-total score), and
the subscales autonomy, cognitive functioning, and interpersonal
relationships (See Fig. 1 and Supplemental Fig. 2).
4. Discussion
In the present study, we compared the neurocognitive and












0.4191 7 (20.6%) 6 (13.6%) – 0.3801
0.1431 9 (26.5%) 7 (15.9%) 1 (2.9%) 0.2241,*
0.2641 5 (14.7%) 4 (9.1%) – 0.4131
0.1341 7 (20.6%) 11 (25%) – 0.6981
0.1201 1 (2.9%) 4 (9.1%) – 0.2851
0.7901 2 (5.9%) 7 (15.9%) – 0.1831
 %) 1 (2.9%) 4 (9.1%) 34 (97.1%) 0.2851,*
%) 0.2641,* 11 (32.4) 27 (61.4%) 35 (100%) 0.0151,*
) 0.7031,* 8 (23.5%) 10 (22.7%) 5 (14.3%) 0.8761,*









0.1331 1.12 (0.49) 1.07 (0.55) – 0.6781
5) 0.1842 2.18 (1.1) 2.36 (1.08) 1.94 (0.90) 0.2182
0.5383 0.65 (0.09) 0.65 (0.12) – 0.9883
90.9) 0.7843 268.2 (180.3) 318.9 (247.4) 547.9 (363.5) 0.5413
ut history of psychotic symptoms; BD-P: Patients with bipolar disorder with history
sychotics; MS: Mood stabilizers; E-CPZ: mg equivalents of Chlorpromazine.
Table 3
Neurocognitive measures (z scores). Repeated measures analysis of variance of patients and healthy controls (Covariates: Hamilton Depression Rating Scale at T1 and T2,
Young Mania rating scale at T1).















































































































































































































































































































































































































































HC: Healthy controls; BD-NP: Patients with bipolar disorder without history of psychotic symptoms; BD-P: Patients with bipolar disorder with history of psychotic symptoms;
SZ: Patients with schizophrenia; TMT: Trail Making Test; ROCFT. Rey–Osterrieth Complex Figure Test; WCST: Wisconsin Card Sorting Test; CPT: Continuous Performance Test.
1 HC > BD-NP, BD-P, SZ.
2 HC > BD-P, SZ.
3 HC, BD-NP > BD-P, SZ.
4 HC > BD-P, SZ; BD-NP > SZ.
5 HC > SZ.
64 E. Jiménez-López et al. / European Psychiatry 56 (2019) 60–68and without a lifetime history of psychosis, a group of stabilized
patients with schizophrenia, and a group of healthy controls,
during a five-year follow-up. Three main findings should be
highlighted.
First, we did not find evidence of progression either in the
neurocognitive or in the psychosocial impairment in any of the
three groups of patients in relation to HC. The stability found in the
neurocognitive impairment is in accordance with the results
obtained in most longitudinal studies which have examined
the course of neurocognitive function both in patients with BD[31,54–56], and patients with SZ [57–59]. Likewise, in accordance
with our results, other authors could not establish a progressive
course of the psychosocial impairment in patients with BD [35], or
in patients with SZ [60,61]. In this regard, although it cannot be
dismissed the possibility of a subset of patients with BD with a
progressive course [39], our results suggest that the presence of a
history of psychotic symptoms is not associated with a progression
of the neurocognitive or psychosocial impairment.
Second, in line with the results obtained in our cross-sectional
study [28], BD-P and BD-NP have a neurocognitive profile of similar
Fig. 1. Course of neurocognitive and functional outcome of patients with bipolar disorder, with (BD-P) and without a history of psychosis (BD-NP), patients with
schizophrenia (SZ) and healthy controls (HC): A) z-scores of the neurocognitive composite index (NCI) at baseline (T1) and at follow-up of five years (T2); B) Total score of
function dimension of the Global Assessment of Functioning (GAF-F); C) Total score of the Functioning Assessment Short Test (FAST).
Table 4
Repeated measures analysis of variance of patients and healthy controls for neurocognitive and functional measures. Significance of test post-hoc (Bonferroni test).
BD-NP vs HC BD-P vs HC SZ vs HC BD-NP vs BD-P BD-NP vs SZ BD-P vs SZ
NCI .002 .000 .000 NS NS NS
Speed processing index .001 .000 .000 NS NS NS
TMT-A NS .040 .030 NS NS NS
Digit-symbol coding .001 .000 .000 NS NS NS
Verbal fluency (categ) NS .000 .000 NS NS NS
Working memory index NS .006 .001 NS .005 NS
Digit span backward NS .035 .022 NS NS NS
Letter-number NS .004 .000 .007 .000 NS
Verbal memory index .025 .009 .012 NS NS NS
Learning .015 .003 .001 NS NS NS
Immediate free recall .019 .003 .004 NS NS NS
Delayed free recall .009 .005 .006 NS NS NS
Recognition NS NS NS NS NS NS
Visual memory index .001 .003 .001 NS NS NS
ROCFT immediate recall .001 .003 .000 NS NS NS
ROCFT delayed recall .002 .004 .002 NS NS NS
Executive function index .008 .002 .000 NS NS NS
WCST No. categories .009 .031 .001 NS NS NS
WCST perseverative errors .004 .010 .000 NS NS NS
TMT-B .020 .002 .001 NS NS NS
Verbal fluency (FAS) NS NS NS NS NS NS
Stroop NS NS .011 NS NS NS
Attention index NS .024 .009 NS NS NS
CPT hits NS .015 .027 NS NS NS
CPT sensitivity A NS NS .008 NS NS NS
GAF-F NS .000 .000 .049 .000 NS
FAST total score NS .000 .000 .033 .000 .005
Autonomy NS NS .000 NS .000 .021
Occupational functioning NS .000 .000 .016 .000 NS
Cognitive functioning NS NS .000 NS .000 .001
Financial issues NS NS .004 NS .026 NS
Interpersonal relationships NS .001 .000 .010 .000 .000
Leisure time .000 .000 .000 NS .035 NS
HC: Healthy controls; BD-NP: Patients with bipolar disorder without history of psychotic symptoms; BD-P: Patients with bipolar disorder with history of psychotic symptoms;
SZ: Patients with schizophrenia; TMT: Trail Making Test; ROCFT. Rey–Osterrieth Complex Figure Test; WCST: Wisconsin Card Sorting Test; CPT: Continuous Performance Test;
GAF-F: Function dimension of the Global Assessment of Functioning; FAST: Functioning Assessment Short Test.
E. Jiménez-López et al. / European Psychiatry 56 (2019) 60–68 65characteristics, with only slight differences found between them,
circumscribed to the working memory domain. Similarly, other
authors did not find relevant neurocognitive differences between
these two subsets of patients [24,27,62–64], even in early stages BD[44,65], although there exist some discrepant findings [18,66]. In
any case, there is broad agreement on the presence of an
overlapping in the neurocognitive performance of both groups
of patients in a way that the differences found are subtle [18]. On
Table 5
Functional outcome measures. Repeated measures analysis of variance of patients and healthy controls (Covariates: Hamilton Depression Rating Scale at T1 and T2, Young
Mania rating scale at T1).


















































Autonomy 0.1 (0.2) 1.1 (1.9) 2.1 (3.1) 4.5 (3.8) 0.1 (0.4) 2.1 (3.1) 2.1 (3.1) 5.7 (6.9) 0.0002 0.229 0.744
Occupational functioning 2.3 (2.7) 3.9 (5.5) 7.9 (6.5) 11.3 (5.4) 2.5 (2.8) 5.7 (6.7) 8.1 (6.5) 12.2 (5.3) 0.0003 0.167 0.216
Cognitive functioning 0.3 (0.7) 1.5 (2.6) 1.8 (2.3) 4.1 (3.1) 0.3 (0.7) 1.6 (2.7) 1.7 (2.0) 4.1 (3.3) 0.0002 0.087 0.819
Financial issues 0.0 (0.1) 0.4 (0.89) 0.9 (1.6) 1.9 (2.0) 0.0 (0.1) 0.8 (1.6) 1.2 (2.0) 2.0 (2.1) 0.0034 0.817 0.248
Interpersonal
relationships
1.0 (1.1) 2.3 (3.1) 4.2 (4.1) 8.1 (3.8) 1.2 (1.0) 2.1 (2.5) 4.4 (4.1) 7.7 (4.0) 0.0001 0.084 0.124
Leisure time 1.6 (1.3) 3.4 (1.1) 3.7 (1.3) 4.3 (1.8) 1.4 (1.1) 3.4 (1.4) 3.7 (1.3) 4.4 (2.1) 0.0005 0.398 0.969
HC: Healthy controls; BD-NP: Patients with bipolar disorder without history of psychotic symptoms; BD-P: Patients with bipolar disorder with history of psychotic symptoms;
SZ: Patients with schizophrenia; GAF-F: Function dimension of the Global Assessment of Functioning; FAST: Functioning Assessment Short Test.
1 HC, BD-NP > BD-P > SZ.
2 HC, BD-NP, BD-P > SZ.
3 HC, BD-NP > BD-P, SZ.
4 HC > SZ.
5 HC > BD-NP, BD-P, SZ.
66 E. Jiménez-López et al. / European Psychiatry 56 (2019) 60–68the other hand, also a number of studies have found the presence of
differences in the working memory domain [12,18,67–70],
although the effect size is small. Interestingly, in our study, BD-
NP did not differ from the control group. In this regard, it has been
suggested that working memory deficits found in patients with
BD-P could indicate the presence of a possible association between
psychosis and frontal lobe dysfunction [18].
Third, considering psychosocial functioning, while patients
with BD-NP have a level of performance similar to that found in HC,
BD-P had a worse performance than HC on most functional
measures. Likewise, as has been found in other studies, BD-P
showed lower impairment than SZ in overall functioning measures
[71,72]. In addition, BD-P had a worse level of psychosocial
functioning than BD-NP, in a way that we could not replicate the
findings of our previous cross-sectional study [29]. However, the
present results are in accordance with other authors which also
reported that patients with BD-P had a worse functional
performance than patients with BD-NP [20,40–43]. Therefore,
the psychosocial functioning of BD-P would occupy an intermedi-
ate position between the functional impairment of patients with
BD-NP and that of patients with SZ [23].
The current study has several limitations that should be
acknowledged. Most importantly, the small sample size. Another
limitation of the study is that all patients were receiving
pharmacological treatment. It should be noted that a higher
percentage of patients with BD-P were being treated with
antipsychotics. Thus, the possibility of a deleterious effect of
antipsychotics on the level of neurocognitive and psychosocial
functioning cannot be ruled out [73,74]. Finally, a Cronbach alpha
coefficient for the working memory domain of 0.585 could alert
about the appropriateness of the instruments used for measuring
this domain. However, this theoretically low value should be
interpreted cautiously, since it is a coefficient which depends on
the number of items (only two in our case, WAIS-III digit span
backward subtest and letter-number sequencing subtest of the
Wechsler Memory Scale), and the variation of the population where
consistency is evaluated, in such away that higher values of alpha are
expected in homogeneous populations, and our sample included
patients with BD, patients with SZ and control individuals [75].
Despite the mentioned limitations, we should also note several
strengths. First the longitudinal design. Second, the 5-year
duration of the follow-up, which could be considered long enough
to detect changes. Third, the inclusion of a healthy control groupwhich was also assessed after a five-year follow-up. Fourth, the fact
that both patients with BD and patients with SZ were in
symptomatic remission at the two time-points of assessment.
In conclusion, our study highlighted that the course of the
neurocognitive functioning and the functional outcome in both
patients with schizophrenia and patients with bipolar disorder,
including those with a history of psychotic symptoms, is stable.
Likewise, the profile of neurocognitive impairment of patients with
schizophrenia or bipolar disorder, with or without psychotic
symptoms, is similar, with only quantitative differences circum-
scribed to certain domains, such as working memory. Importantly,
the results suggest the existence of a subgroup of patients with
bipolar disorder, characterized by the absence of psychotic
symptoms, which does not show a functional deterioration.
Nevertheless, these results should be considered preliminary,
being necessary longitudinal studies with larger samples and a
longer duration to confirm these findings.
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